Pharmacokinetics of a new inotropic catecholamine in dog plasma using solid phase extraction technology.
The pharmacokinetics of a new inotropic catecholamine, N-[2-(3,4-dihydroxyphenyl)-ethyl]-1-methyl-3-(3-carbomylphenyl)-pr opylamine HCL (KM-13), was studied following i.v. injection of 50 and 100 micrograms/kg doses to dogs. KM-13 was extracted from plasma using Bond-Elut CN columns and quantitated by HPLC with electro-chemical detection. The plasma concentration--time profile of KM-13 following an i.v. bolus was best fitted with a bi-exponential equation and the terminal elimination phase had a half life of about 20 min. The analytical method, with a limit of sensitivity of 2 ng/ml, would appear to have general applicability in studying the pharmacokinetics of synthetic catecholamines.
Dixon
R
R
Schering Research, Miami, Fl. 33169.
Hsiao
J
J
Caldwell
W
W
D000818:Animals; D002316:Cardiotonic Agents / Q000493:pharmacokinetics*; D004280:Dobutamine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004285:Dogs; D005260:Female; D008657:Metabolic Clearance Rate
D002316:Cardiotonic Agents; D004280:Dobutamine; C046155:4-(2-((3-(3-benzenecarboxamide)-1-methylpropyl)amino)ethyl)-1,2-benzenediol